Halozyme priced an upsized private offering of USD 1.3 billion 1.5% convertible senior notes due 2033.
The deal increased from the previously announced USD 1.05 billion size.
Initial purchasers received a 13-day option to buy up to an additional USD 200 million of the notes.
Net proceeds are expected at about USD 1.28 billion, rising to about USD 1.47 billion if the option is fully exercised.
Part of the proceeds are earmarked to repurchase USD 151.7 million of 2027 notes and USD 220 million of 2028 notes, with the remaining funds for general corporate purposes.
HALO•
